Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
Legend Biotech Corp. (LEGN.US) on Tuesday reported strong double-digit revenue growth in last year’s fourth quarter on solid gains for its core Carvykti cancer treatment, lifting the company to a…
BRIEF: Hutchmed’s revenue drops 13% in 2025
Drug developer Hutchmed China Ltd. (HCM.US; 0013.HK) said on Thursday its revenue fell 13% in 2025 to $548.5 million from $630.2 million the previous year, as its profit rose sharply…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
